Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma

Resistance development after long-term sorafenib exposure in hepatocellular cancer cell lines and risk of rebound growth and epithelial to mesenchymal transition.

(2017) Chris Verslype et al.   JOURNAL OF CLINICAL ONCOLOGY

Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion

(2015) Songwang Cai et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF- alpha/TNFR1 pathway in vitro and in vivo

(2015) Tao Yang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer

(2015) Zhengxiang Zhang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targeting c-Met in melanoma

(2014) Deven Etnyre et al.   CANCER BIOLOGY & THERAPY

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

(2014) Q. Xiang et al.   CLINICAL CANCER RESEARCH

The multiple facets of drug resistance: one history, different approaches

(2014) Evandro Niero et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model

(2014) Guo-Hua Deng et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein

(2014) Qing-feng Xiang et al.   LIVER INTERNATIONAL

GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells

(2013) Lily L. Remsing Rix et al.   ACS Chemical Biology

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

(2013) R. Katayama et al.   CANCER RESEARCH

A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases

(2013) R. J. Lee et al.   CLINICAL CANCER RESEARCH

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET

(2013) C. Basilico et al.   CLINICAL CANCER RESEARCH

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma

(2013) Jie Sheng Chu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis

(2012) Yuan Xu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

BBA, a Derivative of 23-Hydroxybetulinic Acid, Potently Reverses ABCB1-Mediated Drug Resistance in Vitro and in Vivo

(2012) Dong-Mei Zhang et al.   MOLECULAR PHARMACEUTICS

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma

(2011) Hanning You et al.   HEPATOLOGY

In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs

(2011) Neelesh Sharma et al.   Therapeutic Advances in Medical Oncology

MAC and Bcl-2 family proteins conspire in a deadly plot

(2010) Laurent M. Dejean et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors

(2010) F. Shojaei et al.   CANCER RESEARCH

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE